作者: Tato, Marta ; Broncano-Lavado, Antonio ; Perez-Cecilia, Elisa ; Cacho, Juana ; Toro, Carlos ; Lopez-Roa, Paula ; Millan, Maria Rosario ; Domingo, Diego ; Salso, Santiago ; Barrado, Laura ; Simon, Maria ; Hernandez, Sara ; Esteban, Jaime ; Valverde-Canovas, Jose F ; Garcia-Martinez, Jesus ; Ruiz-Serrano, Maria-Jesus

Nontuberculous mycobacteria (NTM) are gaining interest with the increased number of infected patients. NTM Elite agar is designed specifically for the isolation of NTM without the decontamination step. We assessed the clinical performance of this medium combined with Vitek mass spectrometry (MS) matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) technology for the isolation and identification of NTM in a prospective multicenter study, including 15 laboratories (24 hospitals). A total of 2,567 samples from patients with suspected NTM infection were analyzed (1,782 sputa, 434 bronchial aspirates, 200 bronchoalveolar lavage samples, 34 bronchial lavage samples, and 117 other samples). A total of 220 samples (8.6%) were positive with existing laboratory methods against 330 with NTM Elite agar (12.8%). Using the combination of both methods, 437 isolates of NTM were detected in 400 positive samples (15.6% of samples). In total, 140 samples of the standard procedures (SP) and 98 of the NTM Elite agar were contaminated. NTM Elite agar showed a higher performance for rapidly growing mycobacteria (RGM) species than SP (7% versus 3%, P < 0.001). A trend has been noted for the Mycobacterium avium complex (4% with SP versus 3% with NTM Elite agar, P = 0.06). The time to positivity was similar (P = 0.13) between groups. However, the time to positivity was significantly shorter for the RGM in subgroup analysis (7 days with NTM and 6 days with SP, P = 0.01). NTM Elite agar has been shown to be useful for the recovery of NTM species, especially for the RGM. Using NTM Elite agar + Vitek MS system in combination with SP increases the number of NTM isolated from clinical samples.

2020-11-25·ACS Applied Materials & Interfaces2区 · 材料科学

Nicotinamide as Additive for Microcrystalline and Defect Passivated Perovskite Solar Cells with 21.7% Efficiency

2区 · 材料科学

Article

作者: Huang, Dejun ; Xiao, Zheng ; Huang, Yuelong ; Zhang, Wenfeng ; Zhou, Weiya ; Ma, Zhu ; Liu, Qianyu ; Jiang, Huifeng ; Yang, Zhiqing

Passivation of electronic defects on the surface and at grain boundaries (GBs) of perovskite films has become one of the most effective tactics to suppress charge recombination in perovskite solar cells. It is demonstrated that trap states can be effectively passivated by Lewis acid or base functional groups. In this work, nicotinamide (NTM, commonly known as vitamin B3 or vitamin PP) serving as a Lewis base additive is introduced into the PbI₂ and/or FAI: MABr: MACl precursor solution to obtain NTM modified perovskite films. It has been found that the NTM in the perovskite film can well passivate surface and GBs defects, control the film morphology and enhance the crystallinity via its interaction with a lone pair of electrons in nitrogen. In the presence of the NTM additive, we obtained enlarged perovskite crystal grain about 3.6 μm and a champion planar perovskite solar cell with efficiency of 21.72% and negligible hysteresis. Our findings provide an effective route for crystal growth and defect passivation to bring further increases on both efficiency and stability of perovskite solar cells.

2020-07-01·Journal of Ocular Pharmacology and Therapeutics4区 · 医学

Carboxyvinyl Polymer and Guar-Borate Gelling System Containing Natamycin Loaded PEGylated Nanolipid Carriers Exhibit Improved Ocular Pharmacokinetic Parameters

4区 · 医学

Article

作者: Avula, Bharathi ; Lakhani, Prit ; Majumdar, Soumyajit ; Patil, Akash ; Taskar, Pranjal

Purpose: Natamycin (NTM) ophthalmic suspension is the only FDA-approved formulation commercially available for treating ocular fungal infections. However, precorneal residence times and losses/drainage remain the foremost challenges associated with current ocular antifungal pharmacotherapy. In our previous investigations, NTM loaded polyethylene glycol nanolipid carriers (NTM-PNLCs) showed enhanced corneal permeation, both in vitro and in vivo. To further improve the corneal retention of NTM-PNLCs, this study aimed to develop a gelling system composed of carboxyvinyl polymer, guar gum, and boric acid in which the NTM-PNLCs were loaded. Methods: A 2³ factorial design was employed in formulating and optimizing the gelling system for NTM-PNLCs, where the independent factors were the gelling excipients (guar gum, boric acid, and Carbopol^® 940) and dependent variables were gelling time, gel depot collapse time, rheology, firmness, and work of adhesion. Optimized gel was evaluated for transcorneal permeation using rabbit cornea, in vitro; and tear pharmacokinetics and ocular biodistribution in male New Zealand White rabbits, in vivo. Results: Optimized NTM-PNLC-GEL was found to exhibit shear thinning rheology, adequate firmness, and spreadability, and formed a depot that did not collapse immediately. In addition, the in vitro transcorneal evaluation studies indicated that the NTM-PNLC-GEL exhibited a lower/slower flux and rate in comparison to Natacyn^® suspension. NTM-PNLC-GEL (0.3%), at a 16-fold lower dose, exhibited mean residence time and elimination half-life comparable to Natacyn (5%), and provided similar in vivo concentrations in the innermost tissues of the eye. Conclusion: The data indicate that the NTM-PNLC-GEL formulation could serve as an alternative during ophthalmic antifungal therapy.

项与 NTM肺病 (丹诺医药) 相关的新闻（医药）

2023-11-20

·美通社

盟科药业抗感染新药MRX-5在澳洲完成第一例受试者入组

上海 2023年11月20日 /美通社/ -- 近日，上海盟科药业股份有限公司（以下简称"盟科药业"）宣布其自主研发的抗生素新药MRX-5澳洲I期临床试验完成了首例受试者给药，这标志着MRX-5的开发正式进入了实质性阶段。 MRX-5是一种新型苯并硼唑类抗生素，用于治疗分枝杆菌属，特别是由非结核分枝杆菌（non-tuberculous Mycobacteria，NTM）引起的感染。非结核分支杆菌是指除了结核分枝杆菌复合群和麻风分枝杆菌之外的一大类分枝杆菌。迄今为止，已经发现了190多种NTM菌种及其14个亚种，最常见的致病性NTM包括鸟分枝杆菌复合群和脓肿分枝杆菌等。非结核分枝杆菌（NTM）种类繁多，NTM病的发病率和患病率持续增长，且药物治疗的疗程长、不良反应多、疗效和预后欠佳，可能导致高发病率与高死亡率相关的衰弱性肺部疾病。NTM患者，尤其是耐药患者的治疗面临极大的挑战，亟需能提高治疗成功率的新药问世。临床前研究显示，MRX-5对于大多数常见的NTM菌都有着良好的抗菌活性和安全性，有望为NTM病的治疗提供一种潜在的新选择。本次开展的是MRX-5 首次应用于人体的临床试验，在澳大利亚Nucleus Network研究中心开展，旨在评估健康受试者口服MRX-5的安全性、耐受性、药代动力学特征及食物影响。该试验此前已获得澳大利亚人类研究伦理委员会（HREC）的批准，并在澳大利亚药品管理局（TGA）完成临床试验备案，预计将在2024年内完成入组工作。未来，盟科药业将积极推进管线各产品的临床研究进度，力争为临床上未被满足的需求提供更多的选择。关于盟科成立于2007年，是一家以治疗感染性疾病为核心，拥有全球自主知识产权和国际竞争力的创新型生物医药企业，致力于发现、开发和商业化针对未满足临床需求的创新药物。自成立之初，公司一直秉承"以良药求良效"的理念，聚焦全球日益严重的细菌耐药性问题，以解决临床难题、差异化创新为核心竞争力，目标为临床最常见和最严重的耐药菌感染提供更有效和更安全的治疗选择。更多信息，敬请访问盟科药业官方网站 www.micurxchina.com，或订阅盟科药业中国官方微信。

临床1期临床研究微生物疗法

100 项与 NTM肺病 (丹诺医药) 相关的药物交易

登录后查看更多信息